

PRECISION INSIGHTS

GPS Cancer® and Liquid GPS™

For Health Plans and Employers

*Precise molecular profiling for informed, personalized
cancer treatment strategies*

Forward-thinking organizations are covering NantHealth molecular profiling so that individuals with cancer will have access to precise and comprehensive information when they need it most.

Cancer affects everyone

Cancer continues to have a significant impact on families – most everyone has been touched by cancer in some way, through a friend, family member, co-worker or themselves.

 15 million

Approximate number of Americans are living with cancer

 1.7 million

new cases are diagnosed each year

 41%

Approximately 41% of Americans will be diagnosed with cancer during their lifetime, and 450 employees out of 100,000 will get cancer this year.

Oncologists use all the information available to make the best decisions for their patients. However, response rates for most cancer therapies remain low, **with 75% of cancer patients receiving no benefit from the offered drug.** As a result, patients must often endure toxic effects of therapies that may provide little clinical benefit. Patients, employers, and insurance providers bear the high cost associated with cancer care.

Source: Spear BB, Heath-Chiozzi M, Huff J. Clinical Application of Pharmacogenetics. Trends in Molecular Medicine, 2001 May;7(5):201-4.

The era of precision medicine is here

Every cancer is unique. We can now know more about each patient's tumor than ever before – knowledge that may help oncologists prescribe more effective treatments and avoid treatments that likely won't be effective. We're entering the era of precision cancer care, where oncologists can select therapies based on an understanding of the unique biology of each patient's cancer.

Precision medicine is positively impacting both cost and quality of care for patients with cancer:

Improved patient outcomes

74% reduction in risk of death or disease progression in melanoma patients with BRAF V600E mutation treated with targeted therapy vs standard of care.

Improved quality of life

52% reduction in tumor recurrence when Herceptin is used in combination with chemotherapy vs chemotherapy alone.

Decreased cost of care

\$604M annual savings when Panitumumab or Cetuximab is limited to colorectal cancer patients whose KRAS gene is not mutated.

Source: The Advisory Board Company Personalized Medicine Investment Playbook (2015). Retrieved from <https://www.advisory.com/-/media/Advisory-com/Research/OR/Events/On-Demand-Webconference/The-Personalized-Medicine-Investment-Playbook.pdf>.



Precision Insights: GPS Cancer + Liquid GPS

When faced with a difficult treatment decision, NantHealth's molecular profiling solutions provide insight into the unique drivers of each patient's cancer and help oncologists select the best treatment options available. These precise tests may reveal therapies with potential benefit and those to which the cancer may be resistant.

Forward-thinking organizations are offering NantHealth molecular profiling solutions as a covered benefit, providing individuals with the comfort that, should they or their dependents develop cancer, their oncologists will have precise and comprehensive information available to inform personalized treatment strategies. Partnering with NantHealth includes access to the following:

GPS Cancer



Precise and comprehensive tissue-based molecular profiling to inform oncologists' personalized treatment strategies.

Liquid GPS



Fast and noninvasive blood-based tumor profiling to monitor and inform treatment when tissue is unavailable.

GPS Care Center – Virtual Center of Excellence



Access for patients and their providers to GPS Nurse Navigators and molecular experts to answer questions, assist in navigation, and provide support with compassion throughout the patient's journey.

Turnkey implementation services



A turnkey deployment strategy, built around robust provider and member engagement services, and integration with key employer and health plan stakeholders.

GPS Cancer and Liquid GPS are performed in CAP-accredited, CLIA-certified labs.



Key benefits

Coverage of GPS Cancer and Liquid GPS brings various opportunities to impact both cost and quality of care for individuals with cancer. By enabling informed therapy selection and utilization, this test may help:

Avoid Ineffective Therapy Usage

By providing molecular insight into sensitivity or resistance to specific drugs, GPS Cancer and Liquid GPS may help oncologists identify regimens that are unlikely to benefit the patient. This insight may help avoid use of high-cost therapies that are unlikely to help the patient.

Decrease Treatment Cycles Through Improved Selection

Therapies selected based on molecular evidence of likely benefit may require fewer cycles to achieve response.

Increase Clinical Trial Participation

For many advanced cancers, standard-of-care drug options are quickly exhausted, and clinical trials represent a source of additional options for patients. GPS Cancer helps identify trials that may be applicable to the patient based on their tumor's molecular profile. Once in a clinical trial, the cost of the therapies are typically covered by the trial.



“I’ve been treating metastatic breast cancer for a long time, and this is really something transformative. We are getting information that we never dreamed of 10 years ago. And to be able to use that to really help these patients that have very limited options - to expand their options and hopefully extend their life - that’s really what makes this so powerful.”

—*Timothy Pluard, MD*
Director, Saint Luke’s Cancer Institute,
Associate Professor of Medicine, University of Missouri-KC.



ABOUT NANTHEALTH

NantHealth's Mission is to improve the delivery of healthcare and optimize patient outcomes by leveraging the latest advancements in precision medicine and software technologies to enable true value based care.

TO LEARN MORE ABOUT NANTHEALTH PRECISION INSIGHTS:

1.844.MY.OMICS | gps@nanthealth.com | www.nanthealth.com

TO LEARN MORE ABOUT OTHER NANTHEALTH SOLUTIONS, INCLUDING EVITI, NAVINET, AND CONNECTED CARE:

1.855.WHY.NANT | www.nanthealth.com

These tests are intended to provide molecular information about a patient's tumor for use by a qualified health care professional in accordance with professional guidelines, and is not conclusive or prescriptive for labeled use of any specific therapeutic product.